Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials

This study analyzes the original and updated clinical trials that led to FDA-approved drug indications in oncology from 2006 to 2017 to assess reduction in clinical trial duration derived from using surrogate end points of response rate or progression-free survival rather than overall survival as…

Read the full article here

Related Articles